Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome
Introduction
Tumor hypoxia predicts an adverse treatment outcome in the radiotherapeutic management of cancer of the head and neck, uterine cervix, and in soft tissue sarcomas [2], [4], [7], [10], [11], [15]. For cervical carcinoma, the significance is independent of other known variables such as tumor stage [10]. Whether such independent significance exists in head and neck cancer as well is not known.
Reoxygenation has been demonstrated to occur early in the course of preoperative irradiation and hyperthermia for soft tissue sarcomas. Improved tumor oxygenation has been correlated with increased likelihood of favorable pathologic response [3]. Treatment induced changes in the oxygenation of head and neck cancer along with any associated clinical significance are less well understood [13]. In a preliminary report, we described worse local control, disease free survival, and overall survival in head and neck cancer patients with tumor median pO2 values <10 mmHg [4]. At that time, most patients had only undergone pretreatment oxygen assessment. Since then the total number of patients enrolled in this study has more than doubled. Our policy has also been revised to incorporate a second set of measurements early in the course of treatment. This report updates our previous experience, evaluates treatment induced changes in tumor oxygenation, and examines the significance of tumor oxygenation in a multivariate setting.
Section snippets
Methods and materials
Patients with newly diagnosed, non-metastatic head and neck squamous carcinoma who were to receive primary radiotherapy were eligible. Patients with stage I/II disease were treated with conventional fractionation to doses of 66–70 Gy. Accelerated hyperfractionation with or without concurrent CDDP/5-FU chemotherapy was employed for more advanced presentations [5]. Post radiation adjuvant neck dissection was planned for N2–N3 neck disease.
Polarographic electrode1
Results
Sixty-three patients underwent pretreatment tumor oxygen assessment from November 1992 to July 1998. Tumor location and treatment parameters are outlined in Table 1. The majority of primary tumors originated in the oropharynx. Approximately half of all primary tumors were stage T3 or T4 while approximately 3/4 of the patients had N2 or N3 cervical lymphadenopathy (Table 2). The median target dose was 69 Gy. Oxygen measurements were obtained from the primary tumor in 24 (38%) patients and from
Discussion
The present study has reconfirmed our initial observation that tumor hypoxia exerts an adverse effect on the radiotherapeutic management of head and neck cancer. LRC, DFS, and S were better by a factor of two in the group of patients with well-oxygenated tumors. The correlations of oxygenation with the outcome endpoints were independent of other clinically important factors such as stage and treatment.
Repeat assessments of tumor oxygenation after 10–15 Gy were unchanged compared to pretreatment
References (17)
- et al.
Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue
Int J Radiat Oncol Biol Phys.
(1998) - et al.
Oxygenation predicts radiation response and survival in patients with cervix cancer
Radiother. Oncol.
(1998) - et al.
Cervix cancer oxygenation measured following external radiation therapy
Int. J. Radiat. Oncol. Biol. Phys.
(1998) - et al.
Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix
Radiother. Oncol.
(1993) - et al.
Variations in tumor oxygen tension (pO2) during accelerated radiotherapy of head and neck carcinoma
Eur. J. Cancer
(1998) - et al.
Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck
Radiother. Oncol.
(1996) - et al.
Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma
Cancer Res.
(1996) - et al.
Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas
Cancer Res.
(1996)
Cited by (502)
Tumor hypoxia and radiotherapy: A major driver of resistance even for novel radiotherapy modalities
2024, Seminars in Cancer BiologyCombination of light and Ru(II) polypyridyl complexes: Recent advances in the development of new anticancer drugs
2022, Coordination Chemistry ReviewsA multi-omics deep learning model for hypoxia phenotype to predict tumor aggressiveness and prognosis in uveal melanoma for rationalized hypoxia-targeted therapy
2022, Computational and Structural Biotechnology Journal